Table 5.
Serum miR-1291 | n | CCL17 > 549 pg/mLn (%) | Anti‐BP180 > 60 U/mL, n (%) |
---|---|---|---|
>0.31 | 23 | 22 (95.65) | 15 (65.22) |
≤0.31 | 22 | 12 (54.55) | 7 (31.82) |
P | 0.001 | 0.025 |
Serum miR-1291 | n | CCL17 > 549 pg/mLn (%) | Anti‐BP180 > 60 U/mL, n (%) |
---|---|---|---|
>0.31 | 23 | 22 (95.65) | 15 (65.22) |
≤0.31 | 22 | 12 (54.55) | 7 (31.82) |
P | 0.001 | 0.025 |